A migraine is a headache that can cause severe throbbing pain or a pulsing sensation, usually on one side of the head. It's often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. According to the world health Organization, Migraine most often begins at puberty, and mostly affects those aged between 35 and 45 years. It is more common in women, usually by a factor of about 2:1, because of hormonal influences. In the coming years, the global Migraine Drugs market is estimated to witness outstanding growth because the demand for migraine drugs is rising steadily all over the world.
The rising prevalence of migraine among individuals of all age groups that need to be subsided with drugs is the major reason to boost the growth of the Migraine Drugs market. As per the Migraine Research Foundation, Migraine is the 3rd most prevalent illness in the world. Nearly 1 in 4 U.S. households includes someone with migraine. Amazingly, 12% of the population – including children – suffers from migraine. 18% of American women, 6% of men, and 10% of children experience migraines. In addition, the usual unhealthy food habits and hectic lifestyle of consumers across the world are the primary drivers that influence the growth of the global migraine drugs market.
Furthermore, the increasing population and growing awareness among consumers regarding the availability of migraine treatment drugs are key factors escalating the growth in the market. Apart from this, the development of advanced drugs by migraine drugs manufacturers is another main factor that boosting the growth of the migraine drugs market.
On the contrary, side effects related to migraine drugs are a factor that hampers the growth of the market. Nevertheless, so far, there has not been any line of treatment apart from prescription drugs to subside the pain. This crucial fact creates enormous opportunities in the Migraine Drugs market.
Covid-19 Impact on Migraine Drugs Market
In addition, the current Migraine Drugs Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Migraine Drugs Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Migraine Drugs Market Segment Overview
Based on Treatment, the Abortive segment has the largest share in the Migraine Drugs market. The abortive segment is further classified into Triptans and Ergot Alkaloids and Others based on the drug class. Triptans are a family of tryptamine-based drugs used as abortive medication in the treatment of migraines and cluster headaches. Triptan drugs work like a brain chemical called serotonin. This helps quiet down overactive pain nerves. In other words, triptans reverse the changes in the brain that caused the migraine. In addition to this, here are seven different triptan medicines plus a combination drug that has a triptan and naproxen, a non-steroidal anti-inflammatory drug (NSAID). A doctor will choose one of them based on symptoms and how long headaches tend to last.
Migraine Drugs Market, By Treatment
- Abortive
- Triptans
- Ergot Alkaloids
- Others
- Prophylactic
- Botulinum Toxin
- Topiramate
- Others
· Oral
· Injectable
· Others (Nasal, Spray, Transdermal, Patches)
Migraine Drugs Market, By Distribution Channel
· Hospital Pharmacy
· Retail Pharmacy
Migraine Drugs Regional Overview
In terms of region, North America is anticipated to account for maximum share in the global Migraine Drugs market throughout the forecast period. This is primarily because of the rising healthcare investment by the private and government bodies. Besides this, increasing cases of migraine and the easy availability of specialized migraine treatment are some other key factors that escalating growth of the market in this region. The Asia Pacific is expected to emerge as a significant region in the overall Migraine Drugs market. The increasing cases of the migraine and growing expenditure for the healthcare sector by the government are some prime factors that propelling the growth of the market in this region.
Migraine Drugs Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Migraine Drugs Market Competitor overview
Some key developments and strategies adopted by manufacturers in Migraine Drugs are highlighted below.
· In September 2021, Impel NeuroPharma’s new tackle delivering an outdated migraine drug received FDA approval, giving sufferers a faster-acting manner to reply to debilitating migraine assaults. The Impel product, Trudhesa, is a nasal spray formulation of the migraine drug dihydroergotamine mesylate (DHE). The regulatory determination covers acute therapy of migraine, with or without aura, in adults.
Migraine Drugs Market, Key Players
· Novartis AG
· GlaxoSmithKline plc.
· Allergan Plc.
· Avanir Pharmaceuticals, Inc.
· Janssen Pharmaceutical Company
· Eisai Co.
· Abbott Laboratories
· AstraZeneca
· Endo International Plc.
· Impax Laboratories
· Johnson & Johnson
· Merck & Co.
· Pfizer Inc.
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Migraine Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Treatment
- 5.2.1. Abortive
- 5.2.1.1. Triptans
- 5.2.1.2. Ergot Alkaloids
- 5.2.1.3. Others
- 5.2.2. Prophylactic
- 5.2.2.1. Botulinum Toxin
- 5.2.2.2. Topiramate
- 5.2.2.3. Others
- 5.2.1. Abortive
- 5.3.1. Oral
- 5.3.2. Injectable
- 5.3.3. Others (Nasal, Spray, Transdermal, Patches)
- 5.4.1. Hospital Pharmacy
- 5.4.2. Retail Pharmacy
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America, Middle East and Africa
6. North America Migraine Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Treatment
- 6.2.1. Abortive
- 6.2.1.1. Triptans
- 6.2.1.2. Ergot Alkaloids
- 6.2.1.3. Others
- 6.2.2. Prophylactic
- 6.2.2.1. Botulinum Toxin
- 6.2.2.2. Topiramate
- 6.2.2.3. Others
- 6.2.1. Abortive
- 6.3.1. Oral
- 6.3.2. Injectable
- 6.3.3. Others (Nasal, Spray, Transdermal, Patches)
- 6.4.1. Hospital Pharmacy
- 6.4.2. Retail Pharmacy
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Migraine Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Treatment
- 7.2.1. Abortive
- 7.2.1.1. Triptans
- 7.2.1.2. Ergot Alkaloids
- 7.2.1.3. Others
- 7.2.2. Prophylactic
- 7.2.2.1. Botulinum Toxin
- 7.2.2.2. Topiramate
- 7.2.2.3. Others
- 7.2.1. Abortive
- 7.3.1. Oral
- 7.3.2. Injectable
- 7.3.3. Others (Nasal, Spray, Transdermal, Patches)
- 7.4.1. Hospital Pharmacy
- 7.4.2. Retail Pharmacy
- 7.5.1. UK
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Russia
- 7.5.7. Rest of Europe
8. Asia Pacific Migraine Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Treatment
- 8.2.1. Abortive
- 8.2.1.1. Triptans
- 8.2.1.2. Ergot Alkaloids
- 8.2.1.3. Others
- 8.2.2. Prophylactic
- 8.2.2.1. Botulinum Toxin
- 8.2.2.2. Topiramate
- 8.2.2.3. Others
- 8.2.1. Abortive
- 8.3.1. Oral
- 8.3.2. Injectable
- 8.3.3. Others (Nasal, Spray, Transdermal, Patches)
- 8.4.1. Hospital Pharmacy
- 8.4.2. Retail Pharmacy
- 8.5.1. China
- 8.5.2. India
- 8.5.3. Japan
- 8.5.4. Australia
- 8.5.5. South East Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Migraine Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Treatment
- 9.2.1. Abortive
- 9.2.1.1. Triptans
- 9.2.1.2. Ergot Alkaloids
- 9.2.1.3. Others
- 9.2.2. Prophylactic
- 9.2.2.1. Botulinum Toxin
- 9.2.2.2. Topiramate
- 9.2.2.3. Others
- 9.2.1. Abortive
- 9.3.1. Oral
- 9.3.2. Injectable
- 9.3.3. Others (Nasal, Spray, Transdermal, Patches)
- 9.4.1. Hospital Pharmacy
- 9.4.2. Retail Pharmacy
- 9.5.1. Brazil
- 9.5.2. Saudi Arabia
- 9.5.3. UAE
- 9.5.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Novartis AG
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. GlaxoSmithKline plc.
- 10.6. Allergan Plc.
- 10.7. Avanir Pharmaceuticals, Inc.
- 10.8. Janssen Pharmaceutical Company
- 10.9. Eisai Co.
- 10.10. Abbott Laboratories
- 10.11. AstraZeneca
- 10.12. Endo International Plc.
- 10.13. Impax Laboratories
- 10.14. Johnson & Johnson
- 10.15. Merck & Co.
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
